P/E ratio for Teva Pharmaceutical Industries (TEVA)

P/E ratio history for Teva Pharmaceutical Industries from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novartis NVS	18.1	-59.78%	🇨🇭 Switzerland
Sanofi SNY	13.3	-70.35%	🇫🇷 France
GlaxoSmithKline GSK	13.4	-70.11%	🇬🇧 UK
Pfizer PFE	15.1	-66.32%	🇺🇸 USA
Merck MRK	13.2	-70.71%	🇺🇸 USA
Dr. Reddy's Laboratories RDY	17.4	-61.30%	🇮🇳 India
AstraZeneca AZN	29.7	-33.79%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.